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Abstract
Background: For patients with metastatic renal cell cancer (mRCC) who progressed on vascular endothelial growth
factor (VEGF) receptor tyrosine kinase inhibitor therapy, the orally administered mammalian target of rapamycin
(mTOR) inhibitor everolimus has been shown to prolong progression free survival. Intriguingly, inhibition of mTOR
also promotes expansion of immunosuppressive regulatory T cells (Tregs) that can inhibit anti-tumor immune
responses in a clinically relevant way in various tumor types including RCC. This study intends to investigate
whether the antitumor efficacy of everolimus can be increased by preventing the detrimental everolimus induced
expansion of Tregs using a metronomic schedule of cyclophosphamide.
Methods/design: This phase I-II trial is a national multi-center study of different doses and schedules of low-dose
oral cyclophosphamide in combination with a fixed dose of everolimus in patients with mRCC not amenable to or
progressive after a VEGF-receptor tyrosine kinase inhibitor containing treatment regimen. In the phase I part of the
study the optimal Treg-depleting dose and schedule of metronomic oral cyclophosphamide when given in
combination with everolimus will be determined. In the phase II part of the study we will evaluate whether the
percentage of patients progression free at 4 months of everolimus treatment can be increased from 50% to 70%
by adding metronomic cyclophosphamide (in the dose and schedule determined in the phase I part). In addition
to efficacy, we will perform extensive immune monitoring with a focus on the number, phenotype and function of
Tregs, evaluate the safety and feasibility of the combination of everolimus and cyclophosphamide, perform
monitoring of selected angiogenesis parameters and analyze everolimus and cyclophosphamide drug levels.
Discussion: This phase I-II study is designed to determine whether metronomic cyclophosphamide can be used to
counter the mTOR inhibitor everolimus induced Treg expansion in patients with metastatic renal cell carcinoma
and increase the antitumor efficacy of everolimus.
Trial Registration: ClinicalTrials.gov Identifier NCT01462214, EudraCT number 2010-024515-13, Netherlands Trial
Register number NTR3085.
Background
Approximately 2% of all adult malignancies are kidney
tumors and these account for about 116.000 deaths
worldwide per year [1]. Renal cell carcinoma (RCC) is
the most common primary tumor arising in the kidney
and can be classified into four histological subtypes, i.e.
clear cell (60-80%), papillary (10-15%), chromophobe (5-
10%) and collecting duct carcinoma (< 1%). Approxi-
mately 30% of all patients with RCC has metastatic dis-
ease at presentation and ~50% of patients undergoing
curative surgery can be expected to experience relapse
at distant sites [2,3].
The treatment of metastatic RCC (mRCC) has consid-
erably changed over the last 5 years due to the antitu-
mor efficacy of two groups of targeted agents, namely
agents that inhibit vascular endothelial growth factor
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malian target of rapamycin (mTOR) [4]. The oral multi-
targeted receptor tyrosine kinase inhibitor sunitinib dis-
plays a 31% objective response rate in mRCC patients
with disease stabilization and an increase in median pro-
gression free survival from 5 to 11 months [5]. For
patients with mRCC that progressed on VEGF receptor
tyrosine kinase inhibitor therapy, the orally administered
mTOR inhibitor everolimus was recently shown to pro-
long progression free survival relative to placebo from
1.9 months to 4.9 months (p < 0.001), providing an
important additional therapeutic tool for this patient
category [6,7].
As a derivative of rapamycin, everolimus acts as a sig-
nal transduction inhibitor that is selective for mTOR.
mTOR is a key protein kinase present in all cells which
regulates cell growth, proliferation, angiogenesis, and
survival. The mTOR pathway also plays an important
role in immunoregulation. It critically controls homeos-
tasis and the balance between effector T cells and regu-
latory T cells [8-11]; inhibition of mTOR has been
shown to result in expansion of immunosuppressive reg-
ulatory T cells in vitro and in vivo [12-14].
CD4
+CD25
+ regulatory T cells (Tregs) represent a
functionally distinct lineage of immunoregulatory T
cells crucial for the maintenance of tolerance. Tregs are
critically dependent on the X-chromosome encoded
FOXP3 gene. Mutations in this gene, that encodes the
forkhead/winged-helix family transcriptional repressor
Scurfin, cause a fatal human autoimmune disorder
called IPEX (immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked syndrome) [15]. Tregs have
been shown to suppress anti-tumor immune responses.
In murine models Tregs selectively accumulate in the
tumor and locally maintain a microenvironment that
suppresses the effector function of tumor-infiltrating
cytotoxic lymphocytes. Furthermore, in melanoma
Tregs are overrepresented in metastatic lymph nodes
where they inhibit the function of infiltrating immune
cells. The frequency of Tregs has also been reported to
be increased in the circulation and/or tumor microen-
vironment of patients with various cancers, including
RCC [16]. Of note, both the frequency of circulating as
well as peritumoral Tregs are associated with adverse
outcome in several tumor types [16-18]. Importantly,
depletion of Tregs can take the brake off of suppressed
immune responses and result in a substantially poten-
tiated antitumor immune response. E.g. Treg depletion
can result in the rapid rejection of well-established
tumors, can enhance natural tumor immunosurveillance
and can enhance vaccine efficacy of weakly immuno-
genic melanoma cells [19-21]. Notably, metronomic
administration of cyclophosphamide has consistently
been reported to induce Treg depletion in both murine
and human studies and to result in a restoration of T
and NK effector functions [19,22-24].
Based on these data, the aim of the present study is to
evaluate whether metronomic cyclophosphamide can be
used to counter the mTOR inhibitor everolimus induced
Treg expansion in patients with metastatic renal cell
carcinoma and increase the antitumor efficacy of
everolimus.
Methods/design
I nt h ep h a s eIp a r to ft h es t u d yw ew i l ld e t e r m i n et h e
optimal Treg depleting dose and schedule of metro-
nomic oral cyclophosphamide when given in combina-
tion with a fixed dose of everolimus. Patients will be
enrolled in cohorts of 5 per dose level (see Figure 1).
The dose level showing the most selective depletion of
Tregs will be selected for phase II. In the phase II part
of the study we will evaluate whether the number of
patients who are progression free at 4 months can be
increased from 50% [6,7] to 70% by adding metronomic
cyclophosphamide to everolimus.
Primary objectives
Phase I
Assessment of the recommended dosing and schedule
for metronomic cyclophosphamide with respect to the
optimal selective induction of CD4
+CD25
+ regulatory T
cell depletion, when administered in combination with
fixed dose (10 mg) oral everolimus in patients with
mRCC.
Phase II
To investigate the proportion of patients with mRCC
receiving everolimus and metronomic cyclophosphamide
that is progression free at 4 months.
Phase I and II
To determine the safety and tolerability of the everoli-
mus-cyclophosphamide combination.
Secondary objectives
- To assess the response rate, time to progression and
overall survival of the combination of metronomic
cyclophosphamide and fixed dose oral everolimus.
- Assessment of the immunological effects of combin-
ing metronomic cyclophosphamide with everolimus
focusing on its impact on the number and function of
circulating and tumor-infiltrating CD4
+CD25
+ regula-
tory T cells.
- Assessment of the effect of the combination of
metronomic cyclophosphamide and everolimus on
selected angiogenesis parameters.
- To assess the effect of cyclophosphamide on everoli-
mus drug levels.
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This phase I-II trial is a national multi-center dose-esca-
lation study of low-dose oral cyclophosphamide in com-
bination with a fixed dose of everolimus in patients with
mRCC not amenable to, or progressive after, a VEGF-
receptor tyrosine kinase inhibitor containing treatment
regimen.
Setting
The study is initiated by the department of medical
oncology of the VU University Medical Center and
will be conducted within the context of the Nether-
lands Working Group on Immunotherapy of Oncol-
o g y( W I N - O )w i t hap r e s e n tp a r t i c i p a t i o no f1 3
hospitals.
Eligibility criteria
Inclusion criteria to be eligible for the trial
1. Signed informed consent.
2. Age ≥ 18 years.
3. Histological or cytological confirmed clear-cell
mRCC with progressive disease and not amenable to, or
progressive on, or within 6 months of stopping treat-
ment with a VEGF receptor tyrosine kinase inhibitor
(sunitinib (or pazopanib) ± sorafenib).
4. No other current malignant disease, except for basal
cell carcinoma of the skin.
5. WHO performance status 0-2.
6. Life expectancy of at least 12 weeks.
7. Adequate hematologic function: ANC ≥ 1.5 × 109/
L, platelets ≥ 100 × 109/L, Hb ≥ 6.0 mmol/L.
8. Adequate hepatic function: serum bilirubin ≤ 1.5 ×
ULN, ALT and AST ≤ 2.5 × ULN (or ≤ 5 times ULN if
liver metastases are present).
9. Adequate renal function: calculated creatinine clear-
ance ≥ 50 ml/min.
10. Measurable or evaluable disease as defined by
RECIST 1.1.
11. Patients with reproductive potential must use
effective contraception, negative pregnancy test for
female patients.
12. Able to receive oral medication.
13. Prior therapy with cytokines (i.e. IL-2, interferon) and/
or VEGF-ligand inhibitors (i.e. bevacizumab) is permitted.
14. Patients with brain metastases are eligible if they
have been stable for at least two months post-radiation
therapy or surgery.
Exclusion criteria
1. Currently receiving chemotherapy, immunotherapy,
or radiotherapy, or having received either one of these ≤
Figure 1 Trial design. Patients will be enrolled in cohorts of 5 per dose level. The first 5 patients enrolled will be assigned to dose level 0 in
order to assess immune and anti-angiogenic effects of everolimus monotherapy. In subsequent dose levels the cyclophosphamide dose will be
increased up to a maximum of 150 mg cyclophosphamide twice daily. The dose level showing the most selective depletion of Tregs will be
selected for phase II. Endpoints for the phase I part are safety, immunologic and angiogenesis parameters, response rate and drug levels. In the
phase II part of the study patients will receive 10 mg everolimus per day in combination with the optimal Treg depleting dose
cyclophosphamide. Endpoints for the phase II part are progression free survival, safety, immunologic and angiogenesis parameters and response
rate.
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nib or sorafenib is at least 2 weeks.
2. Known human immunodeficiency virus (HIV) or
other major immunodeficiency.
3. Treatment with immunosuppressive agents within 3
weeks of study entry, except for low dose corticosteroids.
4. Active bleeding diathesis or oral anti-vitamin K
medication.
5. Patients with untreated CNS metastases with clini-
cal symptoms or who have received treatment for CNS
metastases within 2 months of study entry.
6. Active infection or serious intercurrent illness,
except asymptomatic bacteriuria.
7. Presence of unstable angina, recent myocardial
infarction (within the previous 6 months), or use of
ongoing maintenance therapy for life-threatening ventri-
cular arrhythmia.
8. Macroscopic hematuria.
9. Prior therapy with mTOR inhibitors.
10. Known hypersensitivity to everolimus or other
rapamycins (sirolimus/temsirolimus) or to its excipients.
1 1 .P r e g n a n to rn u r s i n gw o m e no rw o m e no fc h i l d -
bearing potential not utilizing an effective contraceptive
method. Men with partners of childbearing potential not
using an effective method of contraception. (Use of
effective contraceptives must continue for 3 months
after the last dose of everolimus).
12. Presence of any significant central nervous system
or psychiatric disorder(s) that would hamper the
patient’s compliance.
13. Uncontrolled diabetes as defined by fasting serum
glucose > 2 ULN, severely impaired lung function.
14. Cirrhosis/chronic active hepatitis/chronic persis-
tent hepatitis, history of hepatitis B or C virus infection.
15. Drug or alcohol abuse.
16. Any other major illness that, in the investigator’s
judgment, substantially increases the risk associated with
the subject’s participation in the study.
Ethics
The study will be conducted in accordance with ethical
principles that have their origin in the Declaration of
Helsinki and are consistent with International Confer-
ence on Harmonisation (ICH) Guidelines for Good Clin-
ical Practice. This protocol has been submitted and
approved by the Medical Ethical Committee of the VU
University Medical Center, Amsterdam, the Netherlands
and the Central Committee on Research Involving
Human Subjects (CCMO). Approval of independent
medical ethics committees of participating hospitals is
required before local initiation of the study protocol.
Oral and written informed consent is obtained from all
patients prior to trial participation.
Safety
All adverse events encountered during the clinical study
will be reported on case report forms (CRF). In case of
a serious adverse event (SAE), the investigator has a
legal requirement to inform the central data manage-
ment office within 24 hr through the web portal Toet-
singOnline. All SAEs must also be reported on the
Adverse Event page of the CRF.
The principal investigators are responsible for the
management of the safety reporting according to local
regulations and guidelines. The study drug license
holder will be provided with copies of all report submis-
sions to regulatory authorities and to the ethical com-
mittee that has approved the study by the principal
investigators. All reported (serious) adverse events will
be discussed by an independent data monitoring com-
mittee. Novartis is responsible to ensure that the latest
investigator’s brochure is used as the source document
for determining the expectedness of a SAE.
Monitoring
The study progress, safety data and data quality will be
monitored by an Independent Data (and safety) Monitoring
Board (IDMB), which will be independent of the trial orga-
nizers. Safety analysis will be performed on a regular basis
and the IDMB will report their findings to the principal
investigators. Once a year throughout the clinical trial, the
principal investigators will submit a safety report to the
accredited METC, including a list of all suspected (unex-
pected or expected) serious adverse reactions, along with an
aggregated summary table of all reported serious adverse
reactions. In addition, a complete safety analysis and an eva-
luation of the balance between the efficacy and the harmful-
ness of the medicine under investigation will be submitted.
Data quality assurance
Data management and trial coordination will be per-
formed via the use of OpenClinica
®.T h i so p e ns o u r c e
web-based software platform for clinical trial data is
compatible with the cancer Biomedical Informatics Grid
(caBIG
®) from the U.S. National Cancer Institute to
manage clinical research data in multi-site studies.
Interim analysis
In the phase II part of the study an interim analysis (IA)
will be performed after treatment of 24 patients that
reached 4-month progression free survival (PFS) or that
progressed within the first 4 months. If the number of
patients progression free at 4 months is < 12 the study
will be terminated due to lack of efficacy. In addition,
the number of patients with combination treatment
related grade ≥ 3 toxicity will be analyzed and if this
number is 12 or higher, the study will be terminated
because of unacceptable toxicity.
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interest, it is possible that there will not be sufficient
evidence to either terminate or continue the trial at the
time of enrollment of the 24th individual. In that case,
the PFS rate at 4 months for the previously started
patients will determine whether or not to halt the trial
due to lack of efficacy. A decision must be made
whether or not to halt enrollment until these 24 patients
have been followed for 4 months or to continue enroll-
ment and risk completing enrollment for the trial before
the interim analysis is made. If only 3 of the first 24
patients have a response, then enrollment will be halted
until the 4-month progression free survival interim ana-
lysis is completed.
Statistical Analysis
In the phase I part of the study, patients are defined as
evaluable if they have completed a minimum of 2 weeks
of combination therapy (i.e. allowing monitoring of
immune effects at t = 2 weeks). Statistical analysis in the
phase II part will be performed according to the inten-
tion-to-treat principle. All patients in this part of the
study that have taken their study medication on at least
one occasion are considered evaluable patients.
The response rate will be determined as the propor-
tion of treated patients who had a partial or complete
response. Time to progression (TTP) and overall survi-
val will be constructed by the use of Kaplan-Meier
curves. TTP will be measured from enrollment and pre-
ferably be defined based on CT-scan imaging based on
Response Criteria according to RECIST (version 1.1) or
alternatively based on clinical evaluation. For TTP ana-
lysis death is considered as progressive disease. Median
TTP and overall survival will be calculated along with
95% confidence intervals. Statistical analyses of changes
in immune and angiogenesis parameters and drug levels
will be performed using paired Student t tests or Wil-
coxon matched pairs tests as appropriate. P < 0.05 will
be considered statistically significant.
T h es a m p l es i z ei nt h eP h a s eIp a r to ft h es t u d yi s
expected to be 10-50 patients. Patients will be enrolled
in cohorts of 5 per dose level. The first 5 patients will
be assigned to dose level 0, to assess the effects of
everolimus monotherapy. Subsequently, 8 combination
therapy dosing levels are planned (see Figure 1). At the
final dose level recommended for the phase II study a
minimum of 10 patients will be treated. For phase II, a
maximum of 56 patients will be included. The sample
size for this part is determined based upon a Bryant
Day Phase II clinical trial design, taking into account
both activity as well as toxicity. Statistical calculation
parameters for the phase II part of this study are:
Probability of Accepting Poor Response (a-r) = 0.1,
Probability of Accepting Toxic Drug (a-t) = 0.1,
Probability of Rejecting Good Drug (b) = 0.1, Unaccep-
table Response Probability (Pr0) = 0.5. Acceptable
Response Probability (Pr1) = 0.7, Unacceptable Non-
toxicity Probability (Pt0) = 0.5, Acceptable Non-toxi-
city Probability (Pt1) = 0.7, Early termination probabil-
ity = Poor Response and Excessive Toxicity = 0.82,
Poor Response and Acceptable Toxicity = 0.59, Good
Response and Excessive Toxicity = 0.59 and Good
Response and Acceptable Toxicity = 0.06. Taking these
parameters into account, the limit for 1st stage reject-
ing of the drug due to inadequate response at interim
analysis will be ≤ 12 patients without being progres-
sion free at 4 months. The upper limit for 2
nd stage
(when total inclusion is completed) rejecting of the
drug due to inadequate response is ≤ 32 patients with-
out being progression free at 4 months. At least 32
patients should be without grade ≥ 3 toxicity due to
therapy, otherwise the combination therapy will be
rejected due to excessive toxicity.
Follow up
Assessments during study treatment phase
- Baseline evaluations are to be conducted within 2
weeks prior to the start of protocol therapy, and com-
prise medical history, physical examination, toxicity
assessment, hematology, serum chemistry, immune and
angiogenesis monitoring, ECG, tumor biopsy (not man-
datory) and, in case of female participants, urine HCG.
Abdominal and chest CT scans must be done within 4
weeks prior to start of therapy.
- Patient visits will be sch e d u l e da t2 ,4a n d8w e e k s
and subsequently 4-weekly. At each visit medical his-
tory, physical examination, toxicity assessment, hematol-
ogy and serum chemistry will be performed.
- Immune monitoring on CD4
+CD25
+FOXP3
+ regula-
tory T cells, conventional T cell subsets, NK cells, invar-
iant CD1d-restricted NKT cells, dendritic cell subsets,
myeloid-derived suppressor cells and cytokine levels will
be performed at baseline and subsequently at 2, 4, and 8
weeks after the start of the study treatment period.
- Angiogenesis monitoring on thrombospondin 1
(TSP-1), VEGF, circulating numbers of platelets and
hematopoietic progenitor cells (HPCs) will be performed
at baseline, week 4 and 8.
- Everolimus and cyclophosphamide drug levels will be
measured during the phase I part of the study at week 4.
- If patients agreed on a tumor biopsy, a second
biopsy will be obtained at week 4.
- CT images will be required at fixed time-points;
baseline, 8 and 16 weeks, and thereafter every 8 weeks
during treatment until progressive disease.
- Adverse events will be reported during the study
treatment phase. Medically significant adverse events
considered related to the investigational product by the
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stable.
Assessments during follow up phase
- At the end of study treatment, medical history and
toxicity will be assessed, and physical examination,
hematology, serum chemistry, immune and angiogenesis
monitoring, abdominal and chest CT scans will be
performed.
- Follow up will last till progressive disease and/or
death of the patient.
Study medication
Everolimus
Everolimus is a selective mTOR signal transduction
inhibitor. It exerts its activity through high affinity inter-
action with an intracellular receptor protein, the immu-
nophilin FKBP12. The FKBP12/everolimus complex
subsequently interacts with the mTOR protein kinase,
inhibiting downstream signaling events. mTOR is mainly
activated via the PI3-kinase pathway through AKT/PKB
and the tuberous sclerosis complex (TSC1/2). mTOR
functions as a sensor of mitogens, growth factors and
energy and nutrient levels, facilitating cell-cycle progres-
sion from G1-S phase in appropriate growth conditions.
This pathway is also involved in the production of pro-
angiogenic factors (i.e. VEGF) and stimulation of
endothelial cell growth and proliferation. mTOR regu-
lates protein translation through inactivating eukaryotic
initiation factor 4E binding proteins and activating the
40S ribosomal S6 kinases, including the HIF-1 proteins
[25].
Everolimus has been investigated in various indica-
tions, namely solid organ transplantation, hematologic
and non-hematologic malignancies, and rheumatoid
arthritis. Based on its potential to act directly on tumor
cells by inhibiting tumor cell growth and proliferation
and indirectly by inhibiting angiogenesis (via inhibition
of tumor cell VEGF production and VEGF-induced pro-
liferation of endothelial cells), everolimus was also inves-
tigated as an anticancer agent.
Everolimus has been evaluated clinically in patients
with mRCC who failed a previous VEGF receptor tyro-
sine kinase inhibitor treatment and with several other
solid malignancies in investigator sponsored studies.
Daily doses of 5 and 10 mg have shown target inhibition
with satisfactory tolerability in most patients. In general,
everolimus is well tolerated and the safety profile is con-
sidered favorable and distinct from that of traditional
chemotherapy [6,7].
Cyclophosphamide
Cyclophosphamide is an alkylating agent that mediates
crosslinking of DNA. It is frequently used in high doses
in the treatment of several malignancies [26] and
induces improved immune responses both in murine
and human studies, when used in low doses due to
induction of Treg depletion [19,22-24]. Furthermore,
depletion of Tregs using metronomic oral cyclophospha-
mide restores T and NK cell effector functions in end
stage cancer patients [22] and anticancer immunity and
vaccine efficacy in multiple murine models [19,27].
Metronomic cyclophosphamide has also been reported
to inhibit tumor angiogenesis, e.g. by reducing the
mobilization and viability of HPCs and by inducing sus-
tained apoptosis of endothelial cells within the vascular
tumor bed [27-32]. TSP-1, a potent and endothelial cell
specific inhibitor of angiogenesis, appears to be an
important mediator of this process as the antiangiogenic
and antitumor activity of metronomic cyclophosphamide
was abolished in TSP-1 null mice [31]. In elderly breast
cancer patients the addition of metronomic cyclopho-
sphamide to letrozole resulted in lower levels of VEGF
in the tumor [33].
In the present study, cyclophosphamide will be admi-
nistered orally in the dose determined by the dose level
to which the patient is assigned. As cyclophosphamide
requires 4-hydroxylation by cytochrome p450s including
CYP3A4, and everolimus is mainly metabolized by
CYP3A4 in the liver and to some extent in the intestinal
wall, there is a potential interaction between the two
drugs [34]. Therefore, everolimus and cyclophosphamide
drug levels will be determined during this study.
Treatment program
Phase I
Patients will be enrolled in cohorts of 5 per dose level.
The first 5 patients enrolled will be assigned to dose
level 0 in order to assess immune and anti-angiogenic
effects of everolimus monotherapy. The second 5
patients enrolled will be assigned to dose level 1. If
there are ≤ 1 dose-limiting toxicities (DLTs) experienced
by the first 5 patients in a cohort during the first 28
days after the first study treatment, patients will be
entered in the next dose level. Entry of patients into the
expansion cohort will not occur until at least 28 days
after the last patient in the escalation phase received
his/her first study treatment. At the final dose level
recommended for the phase II study a minimum of 10
patients will be treated. Intra-individual dose escalation
is not permitted in order to allow determination of any
possible cumulative effect and to evaluate the inherent
toxicity of the regimen at any given dose level. The 10
patients that are being treat e da tt h ef i n a ld o s el e v e li n
the phase I part will be included in the subsequent
phase II analyses.
In case no depletion of Tregs is observed during the
phase I part of the study, we consider the absence of an
increase in Tregs as the minimally acceptable outcome
for proceeding to the phase II part of the study.
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Up to 56 patients will be treated at the dose level that
has been selected based on its capacity to most selec-
tively deplete circulating Treg levels in the phase I part
of the study. Treatment will be continued until disease
progression and/or death of the patient. In case of pro-
gressive disease, the choice of subsequent therapy is at
the discretion of the investigator.
Discussion
The mTOR inhibitor everolimus prolongs PFS in
patients with mRCC from 1.9 months to 4.9 months
relative to placebo [6,7]. Although it thereby provides an
important therapeutic tool for this patient category,
mTOR inhibitors have also been shown to result in the
expansion of immunosuppressive Tregs. Tregs are able
to suppress antitumor immune responses in a clinically
relevant way and therefore we hypothesize that deple-
tion of Tregs can enhance the antitumor efficacy of
everolimus. Cyclophosphamide has consistently been
reported to induce Treg depletion, in both murine and
human studies, when used in low doses [19,22-24].
This phase I-II study is designed to a) obtain the opti-
mal Treg depleting dose of metronomic cyclophospha-
mide when combined with the mTOR inhibitor
everolimus in patients with mRCC and b) to determine
whether this combined treatment results in enhanced
antitumor efficacy of everolimus. The study intends to
increase progression free survival at 4 months from 50%
to 70% by adding metronomic cyclophosphamide to
everolimus.
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